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1 Introduction and background  
Lysosomal storage diseases (LSD) are a heterogenous group of more than 40 
inborn errors of metabolism that are due to specific defects of lysosomal en-
zymes, lysosomal membrane proteins or transporters respectively. All LSD 
are inherited autosomal recessively with the exception of MPS II (M. Hunter), 
Fabry Disease and Danon Disease that are inherited as X chromosomal traits. 
Although individually rare their cumulative prevalence may be as high as 
1:800 in certain ethnic populations. 
Table 1: Number of patients with LSD worldwide and in Austria 
  Number of LSD patients  
world wide /Austria 
Number of treated patients with ERT world wide 
/Austria 
MPS I 
3000/3 600/3* 
MPS II 
2000/10  ?/8 
MPS VI 
1100/1  ?/1 
Pompe 
5000-10000/10 800/9 
Fabry 
4000-5000/25 220/18 
Gaucher 
5000-6000 /23  5200/22 
* 1xERT + 2xBMT 
LSD in general are progressive multiorgan disorder with about 50% having 
significant central nervous involvement. Each LSD comprises a more or less 
unique clinical spectrum with patients at the more severe end showing in-
creased morbidity and mortality whereas patients at the milder end of the 
spectrum having only subtle clinical signs. Patients with mild disease may of-
ten go unrecognized for many years. 
Therapy of LSD consisted mainly of palliative treatment until the recent de-
velopment of enzyme replacement therapies for Gaucher, Pompe and Fabry 
Diseases as well as Mucopolysaccharidosis types I and II (MPS I/II) [Belani et 
al. 1993; Burrow et al. 2007]. 
Lysosomes are intracellular organelles that encompass numerous hy-
drolases and other enzymes that break down different compounds derived 
from intermediary metabolism such as complex lipids, carbohydrates and 
others. 
During the last years the interest for the LSD has significantly increased due 
to the development of novel therapies including enzyme replacement thera-
pies (ERT) and substrate inhibition therapy. Additional therapies such as 
chaperone therapy are currently evaluated in phase I and II trials. Currently 
ERT are available for MPS I, II, VI, Fabry, Pompe and Gaucher diseases. In ad-
dition SRT has been licensed for Gaucher disease.  
LSD are a heterogenous 
goup of inborn errors of 
metabolism … 
 
… which are 
individually rare 
progressive multiorgan 
disorder with different 
clinical occurrence 
palliative treatment 
ERT 
lysosomes are 
intercellular organelles 
ERT, substrate 
inhibition therapy, 
haperone therapy 
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The aim of this paper is to give a brief overview of the treatable LSD, to 
summarise the guidelines for diagnosis, treatment and disease management, 
to summarise data from ERT registers and to analyse eventual fields of con-
flict. For this purpose a thorough Medline search up to August 2008 was per-
formed using the following key words: MPS I, MPS II, MPS VI, Pompe, Fabry, 
Gaucher, enzyme replacement therapy, treatment and registry respectively. 
In addition all pharmaceutical companies involved in manufacturing recom-
binant enzyme and/or substrate inhibition therapies were contacted for fur-
ther information. These companies included Actelion, Biomarin, Genzyme 
and Shire.  
Table 2: Registered enzyme replacement and substrate reduction therapies* 
 
aim of this paper: 
overview of LSD, 
provide guidelines, 
summarise data and 
analyse field of conflict 
LSD Trade name parenchemical nameparen/company Dose/Interval 
      
MPS I Aldurazyme parenLaronidaseparen/Genzyme/BioMarin 0.5 mg/kg/week 
      
MPS II Elapraseparen Idursulfaseparen/Shire 0.5 mg/kg/week 
      
MPS VI Naglazyme parenGalsulfaseparen/BioMarin  1.0 mg/kg/2 weeks 
     
POMPE Myozyme parenAlglucosidase Alfaparen/Genzyme  20 mg/kg/2 weeks 
      
FABRY Replagal parenAgalsidase Alfaparen/Shire 0.2 mg/kg/2 weeks 
  Fabrazyme parenAgalsidase Betaparen/Genzyme  1.0 mg/kg/2 weeks 
      
GAUCHER 
 
Cerezyme parenImigluceraseparen/Genzyme  
Zavesca parenMiglustatparenActelion* 
15-60 Units/kg/2 weeks 
300 mg/day 
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2 Mucopolysaccharidosis  
The MPS are a group of LSD that are caused by the malfunction or absence of 
the specific lysosomal enzyme that is required for break down of glycoso-
aminoglycans (GAG) including heparan and dermatan sulphates [Nelson 
2001; Wraith et al. 1987]. The overall incidence of MPS is approximately 1 in 
25,000 of live births. It is estimated that worldwide 3000 patients suffer 
from MPS I and 1100 from MPS VI. The actual number of patients with MPS 
II is unknown. Frequently patients with MPS require surgical interventions 
due to acute and/or subacute disease related complications. As patients with 
MPS carry a significant perioperative (anesthetic) risk, they should be only 
managed at experienced, well-equipped centers [Belani et al. 1993]. 
2.1 Mucopolysaccharidosis type I parenMPS I, 
Hurler Syndromeparen 
MPS-I is due to deficiency of the intra-lysosomal enzyme α -L-iduronidase 
that leads to progressive storage of glycosaminoglycans (GAG) in all tissues. 
The resulting clinical phenotype follows a spectrum with Hurler Syndrome 
at the severe end, Hurler-Scheie Syndrome as intermediary and Scheie Syn-
drome at the mild end of the disease spectrum. The incidence of MPS I varies 
between 1:76,000 newborns (Hurler Syndrome), 1:280,000 newborns 
(Hurler-Scheie Syndrome) and 1:1.3 million newborns (Scheie Syndrome). 
The cumulative incidence for all three “subtypes” of MPS I is 1:100,000 new-
borns. The cumulative prevalence for all three “subtypes” of MPS I is 0.3 per 
100,000 inhabitants (United Kingdom). MPS I may be more frequent in dif-
ferent ethnic populations. MPS I is inherited as an autosomal recessive trait 
carrying a 25% recurrence risk for future pregnancies. 
2.1.1 Clinical symptoms 
Clinical symptoms may be already present at birth in patients with Hurler 
Syndrome but typically develop during the first year of life. Symptoms may 
include coarse facial features, hepatosplenomegaly, cardiomyopathy, macro-
cephaly, hydrocephalus, obstructive airway disease, gibbus, restricted joint 
movement and recurrent infections of the upper airways and middle ears. 
Early psychomotor development may be normal but may be significantly de-
layed at 1-2 years of age. Patients with Hurler Syndrome, when left un-
treated rapidly progresses afterwards and leads to death during the second 
decade of life [Cleary et al. 1995]. 
Onset of symptoms in patients with Hurler-Scheie Syndrome is typically be-
tween 3 and 8 years of age but most patients are diagnosed much later. Im-
portantly, Central Nervous System (CNS) involvement is less frequent 
and/or less severe, although expectancy of life may be reduced due to car-
diac and pulmonary involvement. In contrast patients with Scheie Syndrome 
have a much later onset of very mild symptoms and are frequently not diag-
nosed accordingly. 
MPS are a group of LSD 
Incidence: 1:25000 live 
births 
cumulative incidence: 
1:100,000 newborns 
Hurler Syndrome: 
clinical symptoms 
present at birth; develop 
durging 1st year of life 
Hurler-Scheie Syndrome 
onset of symptoms 
between 3 and 8 years 
siagnosed much later 
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2.1.2 Diagnosis 
Diagnosis of MPS I is based on demonstration of deficiency of α -L-
iduronidase in either leukocytes or dry blood spots, the latter with the po-
tential for eventual newborn screening. In addition the biochemical analysis 
of urinary GAG may help to raise the suspicion for MPS I. Mutation analysis is 
used for confirmatory diagnosis and prenatal diagnosis respectively.  
2.1.3 Therapy 
Mainstay of therapy for patients with Hurler Syndrome is bone marrow or 
stem cell transplantation (BMT or SCM). The best outcome is obtained when 
transplantation is done before 2 years of age. In addition recombinant en-
zyme (Laronidase/Aldurazyme) manufactured by Genzyme and Biomarin 
for enzyme replacement therapy of all “subtypes” of MPS I was registered 
and approved by FDA in 2003 and EMEA in 2004 [Kakkis et al. 2001; Tho-
mas et al. 2006; Wraith et al. 2004]. The only treatment guidelines published 
to date can be found under the following weblink: 
www.dh.gov.uk/en/Publicationsandstatistics/Publica-
tions/PublicationsPolicyAndGuidance/DH_4118402  [Wraith et al. 
2005]. 
2.2 Mucopolysaccharidosis type II parenMPS II, 
Hunter Syndromeparen 
MPS-II is due to deficiency of the intra-lysosomal enzyme α -L-iduronate sul-
phatase that leads to progressive storage of glycosaminoglycans (GAG) in all 
tissues. The incidence of MPS II varies between 1:65,000 and 1:132,000 
newborns. The prevalence for MPS II is 0.67 per 100,000 inhabitants (United 
Kingdom). MPS II may be more frequent in different ethnic populations. 
2.2.1 Clinical symptoms 
Clinical symptoms may be already present at birth in some patients with 
Hunter Syndrome but typically develop during the first years of life. Symp-
toms may include coarse facial features, hepatosplenomegaly, cardiomyopa-
thy, macrocephaly, hydrocephalus, obstructive airway disease, gibbus, re-
stricted joint movement and recurrent infections of the upper airways and 
middle ears. Early psychomotor development may be normal but may be 
significantly delayed at 1-2 years of age in a subgroup of patients with CNS 
involvement. Patients with the severe form of MPS II when left untreated 
rapidly progresses afterwards and leads to death during the second decade 
of life. In contrast patients with a milder form of MPS II have a much later 
onset of symptoms. 
 
diagnosis: in leukocytes 
or dry blood spots 
mainstay of therapy: 
BMT or SCM 
published treatment 
guidelines 
incidence varies 
between 1:65,000 and 
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milder form: later onset 
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2.2.2 Diagnosis 
Diagnosis of MPS II is based on demonstration of deficiency of α -L-iduronate 
sulphatase in either leukocytes or dry blood spots, the latter with the poten-
tial for eventual newborn screening. In addition the biochemical analysis of 
urinary GAG may help to raise the suspicion for MPS II. Mutation analysis is 
used for confirmatory diagnosis and prenatal diagnosis respectively.  
2.2.3 Therapy 
Recombinant enzyme (Idursulfase/Elaprase) manufactured by Shire for 
enzyme replacement therapy of MPS II was registered and approved by FDA 
in 2003 and EMEA in 2004 [Muenzer et al. 2006]. The only treatment guide-
lines published to date can be found under the following weblink: 
www.dh.gov.uk/en/Publicationsandstatistics/Publica-
tions/PublicationsPolicyAndGuidance/DH_073341 
[Vellodi et al 2007]. Home treatment has been demonstrated to be safe in pa-
tients with MPS II and MPS VI [Bagewadi et al. 2008]. 
2.3 Mucopolysaccharidosis type VI parenMPS VI, 
Maroteaux Lamy Syndromeparen 
MPS-VI is due to deficiency of the intra-lysosomal enzyme N-
acetylgalactosamine-4-sulphatase (arylsulphatase B) that leads to progres-
sive storage of glycosaminoglycans (GAG) in all tissues. The estimated inci-
dence of MPS VI is 1:235,000 newborns. The prevalence for MPS VI is 0.23 
per 100,000 inhabitants.  MPS VI may be more frequent in different ethnic 
populations. 
2.3.1 Clinical symptoms 
Clinical symptoms may be already present during the first year of life, but 
patients with MPS VI are typically brought to medical attention at 2 to 3 
years of age for evaluation of short stature. At that time the patients may also 
have coarse facial features, skeletal abnormalities including bone deformi-
ties, hepatosplenomegaly and inguinal hernias. Typically, intellectual im-
pairment is not observed [Azevedo et al. 2004].  
2.3.2 Diagnosis 
Diagnosis of MPS VI is based on demonstration of deficiency of N-
acetylgalactosamine-4-sulphatase (arylsulphatase B) in leukocytes. In addi-
tion the biochemical analysis of urinary GAG may help to raise the suspicion 
for MPS VI. Mutation analysis is used for confirmatory diagnosis and prena-
tal diagnosis respectively.  
 
diagnosis: leukocytes or 
dry blood spots 
ERT 
safe home treatment in 
patients with MPS II and 
MPS VI 
incidence: 1:235,000 
newborns 
clinical symptoms 
present during fist year 
of live 
medical attention at 2 
to 3 years of age 
diagnosis: in leukocytes 
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2.3.3 Therapy 
Recombinant enzyme (Galsulfase/Naglazyme) manufactured by Biomarin 
for enzyme replacement therapy of MPS VI was registered and approved by 
FDA in 2005 and EMEA in 2006 [Harmatz et al. 2006]. Bone marrow trans-
plantation has been done in single patients with MPS VI with limited benefit. 
Management guidelines for patients with MPS VI have been recently pub-
lished [Guigliani et al. 2007]. Home treatment has been demonstrated to be 
safe in patients with MPS II and MPS VI [Bagewadi et al. 2008]. 
2.4 Pompe Disease parenGlycogen Storage Disease 
Type II parenGSD-IIparen 
Pompe Disease (PD) is due to intra-lysosomal storage of glycogen secondary 
to deficiency of acid α-glucosidase (GAA). The resulting clinical phenotype 
comprises a clinical spectrum with the infantile-onset phenotype at the se-
vere end and the adult-onset phenotype at the mild end of the disease spec-
trum. 
2.4.1 Clinical symptoms 
All patients with PD have a variable albeit progressive intra-lysosomal gly-
cogen storage in skeletal muscles, heart and smooth muscles with resulting 
organ damage and ultimate organ failure. The rate of glycogen accumulation 
depends on residual enzyme activity, environmental factors (nutrition), 
physical activity and yet unkown genetic modifier. Patients with the same 
haplotypes may in fact exhibit different clinical phenotypes. 
PD is classified into two separate categories - infantile-onset and late-onset - 
based on age of onset of symptoms, although there may be significant over-
lap between the two. It is preferred to view the clinical phenotype of PD as 
clinical disease spectrum similarly to other inborn errors of metabolism with 
a severe and a mild end of the clinical spectrum based on severity of clinical 
symptoms in relation to age of onset.  
2.4.2 Infantile-onset PD 
Patients with infantile-onset („classic“) PD present with progressive left ven-
tricular hypertrophy and generalised muscular hypotonia („floppy infant“) 
and typically die within the first year of life due to cardio-respiratory failure. 
Significant cardiomyopathy may already be present in-utero and readily de-
tected by prenatal ultrasound. In addition electrocardiogramm may show 
conduction abnormalities including short PR intervals and tall QRS com-
plexes as well as Wolf-Parkinson-White syndrome in some patients. Addi-
tional symptoms include macroglossia, heptomegaly, splenomegaly and 
feeding difficulties. Data from more than 150 patients with infantile-onset 
PD revealed a median age at first symptoms from 1.6 to 2 months and the 
median age of death from 6.0 to 8.7 months [Di Rocco et al. 2007; Kishnani et 
al. 2006a]. 
ERT 
 
BMT with limited 
benefit 
infantile-onset vs. adult-
onset phenotype 
variable albeit 
progressive intra-
lysosomal glycogen 
storrage in skeletal 
musclues, heart and 
smooth muscles 
2 categories of PD: 
infantile onset and late-
onset 
patients usually die 
within the first year of 
life due to 
cardorespiratory failure 
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Neurological symptoms in infantile-onset PD are not readily observed due to 
early death within the first year. The advent of enzyme replacement therapy 
and the increased survival rate in infants treated early have uncovered neu-
rological manifestions of PD related to cochlear dysfunction and delayed 
myelination respectively, that have not been reported previously [Chien et 
al. 2006]. Involvement of the central and peripheral nervous systems is due 
to progressive storage of glycogen.  
2.4.3 Late-onset PD 
The leading clinical symptom in patients with late-onset PD („non-classic“, 
childhood, juvenile or adult-onset) is progressive muscle weakness due to 
initial involvement of the muscles of the proximal lower limbs and the 
paraspinal muscles. Additional involvement of the diaphragm and accessory 
respiratory muscles may eventually lead to respiratory failure necessitating 
assisted ventilation even when patients are still ambulatory. Occassionally 
respiratory failure may be the presenting clinical symptom associated with 
frequent upper airway infections, orthopnea, sleep apnea and morning 
headaches [Ausems et al. 1999]. Cardiac involvement is typically not oberved 
in late-onset PD [Di Rocco et al. 2007; Lafore et al. 2001]. 
Vascular involvement of large intracranial blood vessels due to glycogen 
storage in vascular smooth muscle cells leading to cerebral aneurysmata has 
been reported in single patients. 
2.4.4 Diagnosis 
Serum creatine kinase, transaminases and LDH are typically elevated in any 
patient with PD, but may be occasionally within normal limits in single pa-
tients with adult-onset PD. Diagnosis of PD should be sought biochemically 
in leukocytes or dry blood [Kallwass et al. 2007]. Muscle biopsies for primary 
diagnostic purposes are obsolete as the false negative diagnostic rate may be 
significant [Kishnani et al. 2006c]. 
2.4.5 Therapy 
Alglucosidase alfa (recombinant GAA (rhGAA), Myozyme) has been shown 
to be effective in the treatment of patients with early and late-onset PD 
[Amalfitano et al. 2001; Geel et al. 2007; Kishnani et al. 2006c]. The individ-
ual response to enzyme replacement therapy may vary due to development 
of rhGAA specific antibodies, age of presentation and progression of disease. 
The development of rhGAA antibodies may be more frequent in patients 
with absent GAA protein or cross-reacting immunological material (CRIM). 
The absence of CRIM (CRIM negative) may have an impact on the prognosis 
of patients with infantile onset PD. So far induction of immune tolerance to 
reduce rhGAA antibody formation has only been evaluated in GAA knockout 
mice, but to our knowledge not in any patients with PD [Joseph et al. 2008; 
Sun et al. 2007]. Treatment guidelines for PD have been recently published 
[Kishnani et al 2006b].  
neurological symptoms 
not readily observed 
clinical symptoms: 
progressive muscle 
weakness … 
… and occasionally 
respiratory failure 
biochemical diagnosis in 
leukocytes or dry blood 
individual response to 
ERT varies due to 
development of rhGAA 
specific antibodies, age 
of presentation and 
progression of disease 
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2.5 Fabry disease parenFDparen 
Fabry disease (FD) is due to deficiency of the intra-lysosomal enzyme α -
galactosidase A that leads to progressive storage of globotriaosyl ceramide 
(GL-3) in endothelium and renal podocytes. The estimated incidence of FD is 
1:40,000 newborns, although recent studies have demonstrated an incidence 
as high as 1:3,500 male newborns [Spada et al. 2006]. FD is inherited as a X-
chromosomal trait, although both females and males with FD are almost at 
an equivalent risk of developing severe symptoms.  
2.5.1 Clinical symptoms 
Clincial symptoms are related to progressive storage of GL-3 in vascular en-
dothelium in various organs including central and peripheral nervous sys-
tem, heart, kidneys, eyes among others. In classical FD affected individuals 
may show first symptoms such as acroparesthesia of fingers/toes, chronic 
diarrhea and angiokeratomata respectively, as early as 10 years of age 
[MacDermot et al. 2001; Ramaswami et al. 2006; Ries et al. 2005; Ries et al. 
2003]. In most individuals with classic FD both males and females renal in-
sufficiency develops eventually. In addition patients with FD are at increased 
risk for cerebro-vascular events including stroke [Rolfs et al. 2005]. Cardio-
myopathy may be the only manifestation of patients with atypical FD 
[MacDermot et al. 2001; Senechal et al. 2003]. 
2.5.2 Diagnosis 
Diagnosis of FD is based on demonstration of deficiency of α -galactosidase A 
in leukocytes and/or dry blood spots. Enzyme analysis in dry blood spots 
may be used for newborn screening. It should be noted that not all affected 
females are readily diagnosed due to normal enzyme activity from the non-
mutant X chromosome. In these cases mutation analysis may be the pre-
ferred method for diagnosis. In addition the biochemical analysis of urinary 
GL-3 may help to raise the suspicion for FD Mutation analysis is the gold 
standard and may be used for confirmatory diagnosis and prenatal diagnosis 
respectively. 
2.5.3 Therapy 
Recombinant enzyme replacement therapy for the treatment of FD was ap-
proved by the FDA in 2003 (agalsidase β/Fabrazyme by Genzyme) and by 
EMEA in 2004 (agalsidase β/Fabrazyme by Genzyme and agalsidase  
α /Replagal by Shire) [Ries et al. 2006]. Home therapy is done successfully 
in different countries including the Netherlands and the United Kingdom for 
several years [Cousins et al. 2008; Linthorst et al. 2006]. There have been 
several reports regarding treatment guidelines [Desnick et al. 2003; Eng et 
al. 2006; Ortiz et al. 2008]. 
incidence: 1:40,000 
newborns 
renal insufficiency, 
cerebro-vascular events 
biochemical diagnosis in 
leukocytes and/or dry 
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ERT approved by the 
FDA and by EMEA 
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2.6 Gaucher disease parenGD Iparen 
Gaucher disease (GD) is due to deficiency of the intra-lysosomal enzyme glu-
cocerebrosidase that leads to progressive storage of glucosylceramide in dif-
ferent organs including CNS, liver, spleen, bone marrow and bone. Depend-
ing on the presence or absence of CNS involvement different types of GD are 
distinguished: GD I –non neuronopathic GD, GD II – acute infantile neu-
ronopathic GD, GD III – late neuronopathic GD.  The estimated incidence of 
GD I is 1:57,000 newborns, but may be as high as 1:800 in the Ashkenazi 
Jewish population. GD is inherited as an autosomal recessive trait [Weinreb 
et al. 2008; Zimran et al. 1992]. 
2.6.1 Clinical symptoms 
Patients with GD I may present with anemia, thrombocytopenia, hepa-
tosplenomegaly and symptoms related to bone involvement at any age al-
though most patients present during adulthood. Skeletal symptoms may in-
clude bone pain, pathological fractures and bone deformities. There is no in-
tellectual impairment in patients with GD I.  
Patients with GD II may present during their first months of life with hepa-
tosplenomegaly and significant neurological involvement, muscle spasticity 
and eye movement disorder. Death usually occurs within the first two years 
of life. Patients with GD III present similarly but during adulthood. Progres-
sion of symptoms is much slower.  
2.6.2 Diagnosis 
Diagnosis of GD is based on demonstration of deficiency of glucocerebrosi-
dase in leukocytes and/or dry blood spots. Enzyme analysis in dry blood 
spots may be used for newborn screening. In addition chitotriosidase and 
ferritin levels may be used as biomarker reflecting storage in organs. Muta-
tion analysis is the gold standard and may be used for confirmatory diagno-
sis and prenatal diagnosis respectively. 
2.6.3 Therapy 
Recombinant enzyme replacement therapy for the treatment of GD was ap-
proved by the FDA in 1993 (Imiglucerase/Cerezyme by Genzyme) [Pas-
tores et al. 1993; Weinreb et al. 2002; Wenstrup et al. 2007]. The first prod-
uct for ERT has been approved already in early 90’s [Barton et al. 1991; 
Grabowski et al. 1995]. Oral substrate reduction therapy for GD has been ap-
proved in 2006 (Miglustat/Zavesca by Actelion) [Weinreb et al. 2005]. 
There have been several reports regarding treatment guidelines [Desnick et 
al. 2003; Eng et al. 2006; Ortiz et al. 2008; Pastores et al. 2004] 
 
incidence of GD I: 
1:57,000 
depending of the 
involvement of CNS 
different types of GD 
are distinguished 
 
GD I: symptoms occur at 
any age; usually during 
adulthood 
GD II: symptoms first 
months of life 
GD III: symptoms occur 
during adulthood.  
biochemical diagnosis in 
leukocytes and/or dry 
blood spots 
gold standard: Mutation 
analysis 
ERT approved by FDA 
oral substrate reduction 
therapy 
 
Enzym Replacement Therapy for Lysosomal Storage Diseases 
14 LBI-HTA | 2008 
Table 3: Side effects of enzyme replacement therapies  
 
 
Laronidase/MPS I Mild to moderate infusion related hypersensitivity reactions: 
  flushing, fever, headache, skin rash 
Idursulfase/MPS II Mild to moderate infusion related hypersensitivity reactions:  
  respiratory distress, hypotension, fever, headache, skin rash, 
 fever, joint pain 
    
Galsulfase/MPS VI No infusion related reactions reported 
    
Alglucosidase Alfa/ 
Pompe Disease 
Mild to moderate infusion related hypersensitivity reactions: 
Respiratory distress, hypotension, fever, headache, skin rash, 
  fever. Severity of reaction may not be readily distinguished  
  from the underlying clinical phenotype 
Agalsidase Alfa/ 
Fabry Disease 
Mild to moderate infusion related hypersensitivity reactions: 
Respiratory distress, hypotension, fever, headache, skin rash. 
    
Agalsidase Beta/ 
Fabry Disease 
Mild to moderate infusion related hypersensitivity reactions: 
Respiratory distress, hypotension, fever, headache, skin rash. 
   
   
Imiglucerase/ 
Gaucher Disease 
Mild infusion related hypersensitivity reactions. 
 
Mucopolysaccharidosis  
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Table 4: Clinical symptoms of treatable LSD 
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3 Disease registries 
There are company sponsored disease registries including the MPS I registry 
(Genzyme), HOS (Hunter Outcome Survey, Shire), Fabry registry (Genzyme), 
FOS (Fabry Outcome Survey, Shire), Gaucher registry (Genzyme) and Pompe 
registry (Genzyme) respectively. All disease registries are governed by scien-
tific-medical advisory boards at different levels (world-wide and regional) 
appointed by the respective companies. Members of the scientific-medical 
advisory boards are typically clinical experts with a long-standing experi-
ence in the management of patients with lysosomal storage disorders. A 
complete list of members of the medical advisory boards can be found on the 
respective registries homepage (see under websites). A list of treatment cen-
ters can be found in table 5, although this list may not be complete as many 
centers also transfer patients to peripheral satellite clinics. Austria (Olaf A 
Bodamer) is represented in the Hunter Syndrome Expert Council as well as 
the MPS I European Advisory Board and all patients with LSD in Austria are 
included in the respective disease registries. 
3.1 MPS I European Advisory Board 
The role of the advisory board is to provide expert advice in Europe on all 
clinical and scientific aspects related to MPS I and the communication to the 
medical community including management of clinical symptoms and compli-
cations, development of severity scores, recommendations for therapy and 
the use of diagnostic tools. The MPS I European Advisory Board typically 
meets twice a year. 
3.2 Hunter Syndrome European Expert 
Council 
The role of the council is to provide expert advice and guidance in Europe on 
topics such as screening for Hunter syndrome and disease diagnosis, enzyme 
replacement therapy for patients with severe CNS involvement, ERT for very 
young patients, moving ERT into the home setting, investigator-led studies, 
advancing the overall management of patients and evaluating possible com-
plementary therapies and to support the medical communication activities 
by reviewing and finalising core slide presentations on Hunter syndrome 
and its treatment, preparing review articles and providing advice and sup-
port for other media activities. The HOS European Expert Council meets 
twice a year.  
company sponsored 
disease registries 
governed by scientific-
medical advisory boards 
parenworld-wide/regionalparen 
expert advice on all 
clinical and scientific 
aspects related to MPS I 
expert advice and 
guidance on topics such 
as screening, diagnosis, 
ERT, management of 
patients 
evaluating complemen-
tary therapies and sup-
port medical communi-
cation 
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3.3 Fabry Disease European Expert Council 
The role of the council is to provide expert advice and guidance in Europe on 
topics such as clinical aspects and disease evolution of Fabry Disease and 
disease diagnosis, enzyme replacement therapy for male and female pa-
tients, ERT for young oligo- or asymptomatic patients, moving ERT into the 
home setting, investigator-led studies, advancing the overall management of 
patients and evaluating possible complementary therapies and to support 
the medical communication activities. The Fabry European Expert Council 
meets twice a year.  
3.4 Fabry Disease European Advisory Board 
The role of the advisory board is to provide expert advice in Europe on all 
clinical and scientific aspects related to Fabry Disease. Particularly the FD 
board is concerned with the development of investigator-led studies to im-
prove the knowledge on ERT with respect to dosing and treatment efficacy 
and the development of management guidelines and treatment recommen-
dations. The Fabry European Advisory Board typically meets twice a year. 
3.5 Gaucher Disease European Advisory 
Board 
The role of the advisory board is to provide expert advice in Europe on all 
clinical and scientific aspects related to GD with particular emphasis on the 
development of consensus management and treatment guidelines. The GD 
European Advisory Board typically meets twice a year. 
3.6 Pompe Disease European Advisory Board 
The role of the advisory board is to provide expert advice in Europe on all 
clinical and scientific aspects related to PD and the communication to the 
medical community including management of clinical symptoms and compli-
cations, development of severity scores, recommendations for therapy and 
the use of diagnostic tools. The PD European Advisory Board typically meets 
twice a year. 
 
expert advice and 
guidance 
evolution of FD, 
diagnosis, ERT … 
expert advice on clinical 
and scientific aspects 
related to FD 
expert advice on clinical 
and scientific aspects 
related to GD 
expert advice on clinical 
and scientific aspects 
related to PD 
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Table 5: Seletected treatment centers for LSD in the European Community 
EU medical centers     
Gaucher  Disease Fabry Disease Pompe Disease 
Mainz, Germany Mainz, Germany Mainz, Germany  
Cologne, Germany Copenhagen, Denmark Munich, Germany 
Cambrige, UK Graches, France Paris, France 
London, UK Lyon, France Rotterdam, Netherlands 
Manchester, UK Prague, CZ Vienna, Austria 
Vienna, Austria London, UK London, UK 
Warsaw, Poland Amsterdam, Netherlands Manchester, UK 
Milano, Italy Stockholm, Sweden  
Prague, CZ Porto, Portugal   
Amsterdam, NL Madrid, Spain   
Madrid, Spain Kiel, Germany   
  Warsaw, Poland   
  Wu_dieresisrzburg, Germany   
  Manchester, UK   
  Vienna, Austria   
      
MPS I MPS II MPS VI 
Mainz, Germany Mainz, Germany Mainz, Germany  
Warsaw, Poland Manchester, UK Manchester, UK 
Padova, Italy London, UK London, UK 
Zaragosa, Spain Vienna, Austria Graz, Austria 
Prague, CZ Salzburg, Austria Padua, Italy 
Manchester, UK Padua, Italy   
Amsterdam, NL     
Vienna, Austria     
Dublin, Ireland     
Porto, Portugal     
Lyon, France     
Rotterdam, Netherlands     
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4 Potential areas of conflict 
4.1 Treatment costs and reimbursement 
issues 
Enzyme replacement therapy for LSD is expensive (table 4) compared to 
treatment modalities for other rare inborn errors of metabolism (dietary 
therapy, co-factor substitution.). It is recognised that the development of 
drugs and the initiation of phase I-III trials to evaluate safety and efficacy for 
the treatment of a limited number of patients is very costly and therefore not 
very attractive for many pharmaceutical companies. On the other hand “or-
phan drug status” is granted for any newly developed drug that is licensed 
for the treatment for rare disorders (orphan diseases). This status permits 
extended exclusive licensure and return of profit for up to 15 years following 
initial approval by FDA or EMEA respectively. It is not known what percent-
age of the whole sale price (table 4) for each product is return of profit. 
Reimbursement by medical insurance companies and/or public health or-
ganisations may differ from country to country. In Austria reimbursement 
also varies depending in which federal state the affected individual lives or 
which health insurance company is involved. Following the approval of Ela-
prase for the treatment of MPS II the oversight committee for health insur-
ance companies (“Hauptverband der Sozialversicherungsträger”) provided 
direct reimbursement of drug only if the therapy was given in one of three 
recognised metabolic centers (Salzburg, Wien, Graz). Enzyme replacement 
therapy for other LSD including Fabry Disease, Pompe Disease and MPS I are 
given at different levels (at the physician’s office, at the peripheral hospital, 
at the metabolic center).  
 
 
ERT is very expensive 
limited attractiveness 
for pharmaceutical 
companies 
quoteoquotequotequote rphan drug statusquotequotequotequote 
 
reimbursement 
conditions depend on 
the insurance systems 
metabolic centers: 
Salzburg, Wien, Graz 
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Table 6: estimated treatment costs per kg body weight per year in Austria (FAP*-whole sale price (€); KKP*-insurance reimbursement (€) 
Prices LSD Austria    calculations per infusion 
  
packing unit FAP* KKP* dosage 50 kg 
n of vi-
als 
60 kg n of vials 70 kg n of vials 
Cerezyme 200 U vial 1x 929.15 870.55             
Cerezyme 400 U vial 1x 1,833.65 1,741.10 60 U/ kg  3.000 U 7 3.600 U 9 4.200 U  10 
                          
Fabrazyme   5 mg vial 1x 607.55 561.00 1 mg/ kg  50 mg 10 60 mg 12 70 mg  14 
Fabrazyme 35 mg vial 1x 3,915.70 3,745.00            
                          
Myozyme 50 mg vial 10x 5,746.20 5,500.00 20 mg/ kg 1000 mg 20 1200 mg 24 1400 mg 28 
Myozyme 50 mg vial 25x 14,317.95 13,750.00               
                          
Aldurazyme 
 
5.8 mg vial 1x 831.75 770.00 0.5 mg/ kg 25 mg 5  30 mg 5 35 mg 6 
                        
                         
Elprase 6 mg vial 1x 1,249.76  ? 0.5 mg/kg 25 mg 4 30 mg 5 35 mg 6 
                         
Naglazyme 5 mg vial  1x 2,889.95  ? 1.0 mg/kg 50 mg 10 60 12 70 14 
                          
Replagal 3.5 mg vial  1x 4,052.57  ? 0.2/kg  10 3 12 4 14 4 
Potential areas of conflict 
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4.2 Treatment guidelines dashwhom to treat, 
when to treat and when to discontinue 
treatment 
There are only a limited number of published guidelines or recommenda-
tions for treatment and/or management of patients with LSD with the ex-
ception of GD  
[www.dh.gov.uk/en/Publicationsandstatistics/Publications/Publication
sPolicyAndGuidance/DH_4118402 (Wraith et al. 2005.  
www.dh.gov.uk/en/Publicationsandstatistics/Publica-
tions/PublicationsPolicyAndGuidance/DH_073341 Vellodi et al.2007; 
Guigliani et al. 2007; Desnick et al. 2003; Eng et al. 2006; Ortiz et al. 
2008; Pastores et al. 2004] 
Most of the enzyme replacement therapies have been developed and 
initiated over the last few years so that the cumulative experience is 
still limited. There is currently no consensus nor any data to support a 
consensus when to start ERT in male pediatric Fabry patients. Some col-
leagues decide to wait with ERT until the patient develops first symptoms 
(acroparesthesia, diarrhea..). Other colleagues argue that storage of Gl-3 is 
progressive and may damage kidneys irreversibly prior to the onset of clini-
cal symptoms and initiation of ERT.  
In contrast there are no recommendations when to discontinue ERT in pa-
tients with LSD, although discontinuation should be considered in any pa-
tient who is non-compliant or where ERT clearly has not proven to be effec-
tive.  The latter may only be evaluated if therapeutic goals have been formu-
lated at the onset of ERT and are checked at regular intervals to ensure con-
tinued compliance and efficacy of treatment. 
 
limited number of 
published guidelines 
ERT developed and 
initiated over the last 
years… 
… experience is still 
limited 
 
no consensus when to 
start ERT 
no recommendations 
when to discontinue 
ERT 
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